AlphAIalphai — Financial news for AI agents
thebull.com.auJUL 65 min read$BSL

Will BlueScope Steel Shares Continue To Rally? Analyst Points To Further Upside

BlueScope Steel (ASX: BSL) shares are up 30.32% YTD to A$31.46 after a ~10% pullback. Goldman Sachs reinstated coverage with a Buy rating and A$37.70 price target, citing improving steel price spreads, earnings momentum and free cash flow. BlueScope also announced a A$1.00 special dividend (ex 20 Jan 2026) and a A$150m productivity program into FY26.

Original reporting
thebull.com.au
Published Jul 6, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Will BlueScope Steel Shares Continue To Rally? Analyst Points To Further Upside — source image
Source · thebull.com.au
Decision brief

The 30-second read

$BSLBullishMed
01

Why it matters

This piece centers on a fresh sell-side catalyst (Goldman reinstating Buy with a new target) and ties it to operational drivers (steel price spreads, earnings momentum, free cash flow) plus capital returns (special dividend, buybacks) and productivity initiatives under a new CEO.

02

Market read

A broker reinstatement with a quantified upside target can drive incremental positioning, but the thesis remains dependent on cyclical steel spreads and execution of productivity initiatives.

03

What to watch

The article leans on broker assumptions (spreads reverting, productivity execution) but provides no new company datapoint on current spread levels or near-term guidance, increasing execution/cycle risk.

Relevance 7/10Novelty 5/10Timing: after-hours/late-day coverage reinstatement (published 2026-07-06)

Background

BlueScope has been a strong ASX materials performer, with takeover interest previously rejected and management emphasizing undervaluation and medium-term value if spreads/FX normalize.

Company-level read

Ticker impact

$BSLBullishMedium confidence
Context

Goldman Sachs reinstated coverage on BlueScope Steel with a Buy rating and a A$37.70 price target, citing improving spreads and earnings momentum.

Expected impact

Moderate upside bias over days/weeks; upside depends on follow-through in steel spreads and earnings momentum rather than deal speculation.

Evidence & confidence

The article’s actionable catalyst is the fresh broker reinstatement and target, while the fundamental drivers (spreads, earnings momentum, free cash flow) are framed but not newly reported by the company in this text.

Market effects

Sector

Bullish read-through for ASX materials/integrated steel names if investors treat improving spreads and margin recovery as a sector theme.

Regional

Supports sentiment in Australia’s industrials/materials complex, particularly for investors tracking steel demand and cost dynamics.

Global

Highlights global steel spread sensitivity to iron ore/coking coal and construction/manufacturing demand, relevant to broader industrial cyclicals.

Counterpoint

What could challenge this read

The stock’s ~30% YTD run may already price in improving spreads; without a live takeover bid, any spread/macro disappointment could quickly reverse the rally.

Key entities

  • company
    BlueScope Steel

    ASX-listed steelmaker discussed as the subject of Goldman’s reinstated Buy call and the focus of the rally/floor narrative.

  • analyst_firm
    Goldman Sachs

    Reinstated coverage with Buy rating and A$37.70 price target, citing improving spreads and earnings momentum.

  • executive
    Tania Archibald

    New CEO referenced in connection with an extended productivity program.

  • company
    Seven Group Holdings

    Named as part of the consortium that made unsolicited takeover proposals that were rejected.

  • company
    Steel Dynamics

    US partner named in the takeover consortium proposals.

Read at source← All news

Related articles

AUG 17
$BSLMed

BlueScope profit soars 800 per cent as it pivots to shareholder returns

BlueScope reported FY2026 net profit after tax of $802m, up 857% from FY2025, with EBIT of $1.27b. The company attributed the jump to an impairment charge rolling off and said it is shifting from heavy investment to shareholder returns. It declared an unfranked final dividend of 65c and special dividend of 70c per share. Safety and blast furnace upgrade timelines were also discussed.

illawarramercury.com.au3 min
AUG 17
$BSLMedAI 8/10

BlueScope FY profit jumps over 100% on U.S., Asia strength

BlueScope reported annual underlying net profit after tax of A$851.2 million, up from A$420.8 million, citing stronger U.S. steel spreads and improved Southeast Asian operations. It forecast underlying EBIT for 1H 2027 of A$860 million to A$960 million. BlueScope declared a final dividend of 65 cents and a special dividend of 70 cents per share, and plans to return A$3 per share in FY2027.

investing.com3 min
JUN 5
$INFYMed

TCS, Infosys shares on hold? Time to buy midcap IT stocks, says Antique

Antique Stock Broking kept “Hold” ratings on largecap IT services—TCS (target Rs 2,900), Infosys (Rs 1,390), HCL Tech (Rs 1,430), Wipro (Rs 225), Tech Mahindra (Rs 1,550)—and preferred select midcaps Coforge (Rs 5,625) and Mphasis (Rs 1,875) as well as other “Buy” names. It cited cautious US retail commentary, fading tax-refund benefits, and macro risks. It expects gradual erosion of traditional services and says AI monetization is the key theme.

businesstoday.in3 min
SEP 8
$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.

yahoo.com3 min
SEP 8
$BEMed

Bloom Energy (BE) Joins S&P 500: Can Its AI Rally Continue?

Bloom Energy (BE) will join the S&P 500 on September 21, effective before market open. The company's stock surged over 150% in 2026, driven by demand for its power solutions in AI data centers. Bloom Energy reported 166% revenue growth in Q2 and raised its full-year revenue outlook to $3.9B-$4.2B. The company has partnerships with Oracle and Brookfield Asset Management, aiming to accelerate fuel cell deployment.

insidermonkey.com2 min